创伤出血性休克患者使用前列环素:一项随机临床试验
这项多中心、随机、盲法、由研究者发起的临床试验纳入229例创伤出血性休克患者,按1:1随机分配接受72小时伊洛前列素(1 ng/kg/min)或安慰剂输注。主要终点28天内无ICU生存天数在伊洛前列素组为15.64天,安慰剂组为13.99天(校正均差-1.63天,95%CI -4.64至1.38天;p=0.28),差异无统计学意义。28天死亡率两组分别为18.8%和19.6%(OR 1.01,95%CI 0.51-2.0;p=0.97)。住院时间伊洛前列素组为19.96天,安慰剂组为27.32天(校正均差7.84天,95%CI 1.66-14.02天;p=0.01),差异有统计学意义。作者认为伊洛前列素安全,且观察到住院时间显著缩短,但需进一步研究。
要点
- 在229例创伤出血性休克患者中,伊洛前列素1 ng/kg/min持续72小时输注未显著增加28天内无ICU生存天数:15.64天 vs 13.99天(校正均差-1.63天,95%CI -4.64至1.38天;p=0.28)。
- 28天全因死亡率伊洛前列素组18.8% vs 安慰剂组19.6%(OR 1.01,95%CI 0.51-2.0;p=0.97),无统计学显著差异。
- 住院时间伊洛前列素组19.96天 vs 安慰剂组27.32天(校正均差7.84天,95%CI 1.66-14.02天;p=0.01),差异有统计学意义。
- 作者认为伊洛前列素安全,并建议对创伤休克患者的前列环素应用需进一步研究。
适用人群与场景
- 创伤出血性休克患者,共229例,多中心随机分组。
处置流程与药物剂量
- 伊洛前列素(前列环素类似物)1 ng/kg/min持续静脉输注72小时,与安慰剂对照。
研究设计与关键结果
- 多中心、随机、盲法、由研究者发起的临床试验,纳入229例创伤出血性休克患者,1:1随机接受72小时伊洛前列素(1 ng/kg/min)或安慰剂输注。
- 主要终点28天内无ICU生存天数:伊洛前列素组平均15.64天 vs 安慰剂组13.99天(校正均差-1.63天,95%CI -4.64至1.38天;p=0.28)。
- 28天全因死亡率:伊洛前列素组18.8% vs 安慰剂组19.6%(OR 1.01,95%CI 0.51-2.0;p=0.97)。
- 住院时间:伊洛前列素组平均19.96天 vs 安慰剂组27.32天(校正均差7.84天,95%CI 1.66-14.02天;p=0.01)。
证据类型、等级与局限
- 证据类型:多中心、随机、盲法、由研究者发起的临床试验。
- 证据等级:治疗/照护管理;Level II。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为伊洛前列素在创伤出血性休克患者中安全,且观察到住院时间显著缩短,但未显著增加28天内无ICU生存天数。
- 作者建议对创伤休克患者的前列环素应用需进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: A main cause of trauma morbidity and mortality is multiple-organ failure, and endotheliopathy has been implicated. Pilot studies indicate that low-dose prostacyclin improves endothelial functionality in critically ill patients, suggesting that this intervention may improve trauma patient outcome.
METHODS: We conducted a multicenter, randomized, blinded, clinical investigator-initiated trial in 229 trauma patients with hemorrhagic shock who were randomized 1:1 to 72 hours infusion of the prostacyclin analog iloprost (1 ng/kg/min) or placebo. The primary outcome was the number of intensive care unit (ICU)-free days alive within 28 days of admission. Secondary outcomes included 28-day all-cause mortality and hospital length of stay.
RESULTS: The mean number of ICU-free days alive within 28 days was 15.64 days in the iloprost group versus 13.99 days in the placebo group (adjusted mean difference, -1.63 days [95% confidence interval (CI), -4.64 to 1.38 days]; p = 0.28). The 28-day mortality was 18.8% in the iloprost group versus 19.6% in the placebo group (odds ratio, 1.01 [95% CI, 0.51-2.0]; p = 0.97). The mean hospital length of stay was 19.96 days in the iloprost group versus 27.32 days in the placebo group (adjusted mean difference, 7.84 days [95% CI, 1.66-14.02 days], p = 0.01).
CONCLUSION: Iloprost did not result in a statistically significant increase in the number of ICU-free days alive within 28 days of admission, whereas it was safe and a statistically significant reduction in hospital length of stay was observed. Further research on prostacyclin in shocked trauma patients is warranted.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level II.
参考来源
- Johansson PI, Fenger Eriksen C, Bovbjerg PE, et al. Prostacyclin in trauma patients with hemorrhagic shock: A randomized clinical trial. J Trauma Acute Care Surg. 2023. PMID: 37962189. doi:10.1097/TA.0000000000004150
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。